Aspirin, COX-2 inhibitors both reduce breast cancer risk

  • Kehm RD & al.
  • Breast Cancer Res
  • 18 Apr 2019

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Regular use of aspirin and COX-2 inhibitors was associated with significant decreases in breast cancer risk among women with familial or genetic risk.

Why this matters

  • Associations were not modified by familial or genetic risk, suggesting that regular aspirin and COX-2 inhibitor use may have an even greater benefit for those at higher risk.

Study design

  • Prospective cohort of 5606 women with no history of breast cancer and combined retrospective+prospective cohort of 8233 women with and without a history of breast cancer.
  • Funding: USA National Cancer Institute; others.

Key results

  • Regular aspirin use was associated with decreased breast cancer risk in the combined cohort (HR, 0.63; 95% CI, 0.57-0.71), but did not achieve statistical significance in the prospective cohort (HR, 0.61; 95% CI, 0.33-1.14).
  • Regular COX-2 inhibitor use was associated with a significant decrease in breast cancer risk in both the prospective (HR, 0.39; 95% CI, 0.15-0.97) and combined (HR, 0.29; 95% CI, 0.23-0.38) cohorts.
  • Associations were similar when stratified by women not known to be mutation carriers and those with BRCA1 and BRCA2, as well as by estrogen receptor status and attained age.
  • No association with use of other NSAIDs or acetaminophen.

Limitations

  • No data on dosage and only limited data on duration of use.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit